Patent ID: 9624525
Date: 2017-04-18
CPC Classifications: A61B,A61K,A61P,C12Q,C12Y,G01N,Y10S,Y10T

Claim:
1. A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes; the method comprising: a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual; b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase; c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual; and d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD, wherein a decrease in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates the PDD has improved.